9
Active INDs
4
Technology Platforms
600
Employees

Recent News

Athenex Expands its Strategic Partnership with Guangzhou Xiangxue Pharmaceutical Through a Licensing Agreement for its Product Candidates Oral Paclitaxel and Oral Irinotecan, as well as Tirbanibulin Ointment, in China, Hong Kong and Macao

Athenex Announces Superior Response and Survival with Lower Neuropathy of a Novel Oral Paclitaxel versus IV Paclitaxel in Treatment of Metastatic Breast Cancer

Athenex Announces Details of Investor Event and Webcast at SABCS on December 13, 2019

Athenex Announces $60 Million Private Placement

Athenex Announces Key Company Activities at San Antonio Breast Cancer Symposium

Athenex, Inc. Announces Third Quarter 2019 Financial Results

Athenex Announces European Commission Grants Orphan Designations for Paclitaxel and Encequidar for the Treatment of Soft Tissue Sarcoma

Athenex Announces Progress Update from Partner Almirall on Tirbanibulin Ointment

Athenex, Inc. to Report Third Quarter 2019 Earnings Results on November 7, 2019

Other Highlights

Photography by Christopher Galluzzo / Nasdaq, Inc.

Photography by Christopher Galluzzo / Nasdaq, Inc.

On June 14, 2017, Athenex celebrated its initial public offering (IPO) at the Nasdaq MarketSite in Times Square.
At the 2019 San Antonio Breast Cancer Symposium, Athenex Oncology raised awareness of chemotherapy induced peripheral neuropathy. Visitors performed everyday tasks, while wearing experiential neuropathy gloves.
Athenex is building a 409,000 square foot manufacturing facility in Dunkirk, NY, with support from New York State.